EGTX — Egetis Therapeutics AB (publ) Cashflow Statement
0.000.00%
Last trade - 00:00
- SEK1.47bn
- SEK1.39bn
- SEK57.60m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -61.4 | -179 | -105 | -194 | -327 |
Depreciation | |||||
Non-Cash Items | -1.15 | 2.03 | 0.228 | 9.4 | 17.7 |
Other Non-Cash Items | |||||
Changes in Working Capital | -0.282 | 42.1 | -28.3 | 10.9 | 30.7 |
Change in Accounts Receivable | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -62.6 | -135 | -130 | -174 | -278 |
Capital Expenditures | — | -0.024 | -0.172 | 0 | 0 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | -59.5 | -5.79 | -1.7 | 0 |
Acquisition of Business | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | — | -59.5 | -5.96 | -1.7 | 0 |
Financing Cash Flow Items | -4.32 | -22.1 | 0 | -12.6 | -26.2 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 86.7 | 228 | -8.9 | 156 | 459 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 25.2 | 32.8 | -144 | -16.3 | 176 |